Printer Friendly

SYSTEMIX SIGNS COLLABORATIVE AGREEMENT WITH CENTRE LEON BERARD

 PALO ALTO, Calif., July 1 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX) today announced that its wholly-owned subsidiary, SyStemix International S.A.R.L. has signed a scientific and research agreement with Centre Leon Berard in Lyon, a leading bone marrow transplantation center in France. This agreement lays the groundwork for Centre Leon Berard to implement clinical trials initiated by SyStemix for the use of hematopoietic stem cells as an adjunct to cancer chemotherapy and bone marrow transplantation.
 Centre Leon Berard is the second largest comprehensive cancer center in France with 3,00 new tumors diagnosed each year. The center has a staff of 700 employees including 100 doctors who are working on cancer therapy and research. The bone marrow transplant team at Leon Berard is the largest center in Europe for autologous bone marrow transplantation.
 "Centre Leon Berard's clinical expertise in hematology and the treatment of cancer combined with SyStemix' knowledge of hematopoietic stem cells and cell purification creates the medical and science synergies for the successful launch and implementation of clinical trials," said Linda Sonntag, Ph.D., president and CEO of SyStemix, Inc. "We are very proud to initiate our first European clinical collaboration at Centre Leon Berard."
 Centre Leon Berard will house a SyStemix stem cell center directly adjacent to their research hospital. Scientists employed by SyStemix International will staff the center. Their responsibilities will include the processing of human bone marrow or mobilized peripheral blood in an effort to isolate and purify the patient's stem cells.
 "SyStemix' presence on our campus will create a very important opportunity for Centre Leon Berard to participate in the establishment of a revolutionary technology," said Professor Thierry Philip, director of Centre Leon Berard. Dr. Philip will be the principal investigator for the collaborative clinical effort.
 SyStemix, Inc., based in Palo Alto, Calif., is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakarocyte progenitors.
 -0- 7/1/93
 /CONTACT: Linda Sonntag, Ph.D., president & CEO of SyStemix, Inc., 415-813-6510, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-979-9180, for SyStemix, Inc./
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU: JVN

TM -- NY004 -- 7512 07/01/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:371
Previous Article:NEW AMERICAN CLASSIC TO BE LAUNCHED ON FOURTH OF JULY; THE TRIVIAL PURSUIT ALL-AMERICAN EDITION SPOTLIGHTS AMERICAN PRESIDENTS
Next Article:DUPONT TO ACQUIRE ICI'S WORLDWIDE NYLON BUSINESS
Topics:


Related Articles
SYSTEMIX ENTERS STRATEGIC R&D COLLABORATION WITH SANDOZ; COMPANIES TO RESEARCH AND DEVELOP USES FOR HUMAN STEM CELL GROWTH FACTORS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX MOVES TO STATE-OF-THE-ART FACILITY
SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
SYSTEMIX REPORTS 1992 RESULTS
SYSTEMIX HIRES VICE PRESIDENT OF PRECLINICAL RESEARCH
SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX APPOINTS NEW VICE PRESIDENT FOR MEDICAL AFFAIRS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters